Author: Emmanuel, Eric ; Dû, Katell Le ; Gaillard, Sophie ; Allix-Béguec, Caroline ; Septans, Anne-Lise ; Peribois, Anne ; Dômont, Julien ; Dupuis, Olivier

AbstractPurpose The incidence of anemia and its consequences are often underestimated during cancer management. Recommendations were updated in 2010. Methods In this single-centre retrospective study, we assessed patient management before and after the publication of these recommendations. Eligible patients were treated for cancer and warranted overnight hospitalization over two periods (n = 206 in 2011, n = 143 in 2018). The diagnosis of anaemia was defined by a haemoglobin level below 12 and 13 g/dl for women and men, respectively. Results The prevalence of anaemia was 26% in 2011 and 16% in 2018 (p < .001). Biological assessment had changed between the two periods, with more tests of iron metabolism and measurements of inflammatory parameters. Patients hospitalized in 2018 had more advanced cancer and more severe anaemia. Rate of transfusion therapy did not change, but patients with mild and moderate anaemia were transfused less in 2018. Intravenous iron and erythropoietin-stimulating agent were used more frequently in 2018, mainly for mild anaemia and life-threatening anaemia, respectively. Overall survival was poor in both cohorts at 24 months after anaemia diagnosis (15.4% in 2011 and 6.5% in 2018, p = .048). Conclusion Practices have changed in the diagnosis of anaemia and prescriptions for erythropoietin-stimulating agents and intravenous iron have increased. Efforts must continue to explore the causes of anaemia, optimize the quality of life of anaemic patients and reduce transfusions.

The place of the relative at the time of the announcement of cancer progression. BABEL, a mixed-method study

Author: LECOMTE, Thierry ; GYAN, Emmanuel ; HUREAUX, José ; COLOMBAT, Philippe ; LAURENT, Estelle ; INGRAND, Isabelle ; EGRETEAU, Joëlle ; Bourgeois, Hugues ; COJOCARASU, Oana ; ALEBA, Albert

AbstractBackground Few studies have evaluated the place of cancer patient’s relatives during a consultation bringing bad news. Aim To explore how a relative’s presence in these consultations helps communication. Design : Oncologist consultations with patients and relatives for the announcement of cancer progression were recorded, then the different participants completed questionnaires. Answers were further investigated in a few semi-structured interviews. Comparison of quantitative responses (questionnaires) used Wilcoxon's test for matched series. Qualitative analysis (consultations, interviews) used grounded theory. Results were interpreted in a mixed-method integrative approach. This study received the regulatory authorizations. Setting/participants : Patients were aged over 18, followed for cancer in palliative phase, excluding brain tumors and malignant haemopathies, presented renewed disease progression. Relatives were aged over 18 and authorized by the patient to participate. Results 47 documented consultations and 12 interviews (4 triads) were collected. For 93% of patients, the presence of a relative was considered beneficial. Half the relatives, while remaining discreet, nevertheless contributed to the discussion. Although their relationship to time and their expectations may differ, patients and relatives found the consultation positive. However, oncologists did not check what the dyad had retained. They appeared to underestimate the patient's level of understanding (P<0.001) and perceptions of the seriousness of the disease (P=0.009) but not those of relatives. They did not evaluate the relative's state of health. Conclusion Availability of oncologists to patients and families could be improved. Training via simulation sessions should be adapted to communication implying relative.

100 Deals associated with Clinique Chirurgicale Victor Hugo SAS

100 Translational Medicine associated with Clinique Chirurgicale Victor Hugo SAS

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 25 Apr 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Clinique Chirurgicale Victor Hugo SAS

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 25 Apr 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing